GSK's sNDA for Ovarian Cancer Drug Zejula Accepted by FDA

Feb 24, 2020

|

NEW YORK – GlaxoSmithKline said Monday that the supplemental new drug application for niraparib (Zejula) as a first-line maintenance treatment for chemotherapy-responsive advanced ovarian cancer was accepted by the US Food and Drug Administration.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Menu

GSK's sNDA for Ovarian Cancer Drug Zejula Accepted by FDA

To read the full story....

Breaking News

Myriad Genetics BRCA Test to be Reimbursed in Japan

NOTCH Mutations Potentially Predictive for Immunotherapy Response in Lung Cancer

Breast Cancer Subtypes Vary With Indigenous Ancestry in Latin American Women

VBL Therapeutics, NanoCarrier to Expand Clinical Trial of Ovarian Cancer Drug to Japan

BeiGene, Zymeworks Dose First Patient in Phase IB/II Trial for HER2-Positive Cancers

Pancreatic Cancers With TP53 Mutations More Sensitive to Adjuvant Chemo, Study Shows

Featured White Papers

What's Popular?

Myriad Genetics BRCA Test to be Reimbursed in Japan

NOTCH Mutations Potentially Predictive for Immunotherapy Response in Lung Cancer

Adventist Health, CancerIQ Collaboration Identifying More Patients for Guidelines-Supported Genetic Testing

Breast Cancer Subtypes Vary With Indigenous Ancestry in Latin American Women

Metastatic Prostate Cancer Features Linked to Immunotherapy Response, Despite Low TMB

Sponsorships